Proof or Principle? On Economic Modeling to Guide Genomic Testing in Metastatic Colorectal Cancer
Menée à l'aide d'un modèle mathématique, cette étude évalue le rapport coût-efficacité de la recherche de mutations des gènes KRAS et BRAF avant une thérapie ciblée anti-EGFR chez les patients atteints d'un cancer colorectal métastatique
The use of molecular testing to personalize cancer treatment selection is on the rise and has been heralded as a panacea for patients diagnosed with cancer. In principle, the scenario for molecular testing is clearly positive: a relatively inexpensive test that identifies “responders” to expensive therapeutics can improve outcomes for those who receive it while sparing other patients (and society) the risk and expense of medicines that ultimately will not help and sometimes can harm. As with all major advancements in the treatment landscape, a fuller picture of molecular testing can only emerge through experience. That experience inevitably leads to a more nuanced understanding of molecular testing’s impact on outcomes, costs, and value for patients and populations...
Journal of the National Cancer Institute , commentaire, 2012